nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.249	1	CbGbCtD
Raltegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00278	0.0971	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00274	0.0958	CbGpPWpGaD
Raltegravir—UGT1A1—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00236	0.0824	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00184	0.0643	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.0014	0.0489	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00134	0.0469	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.00123	0.043	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.00104	0.0363	CbGpPWpGaD
Raltegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000917	0.032	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.00091	0.0318	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000827	0.0289	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000792	0.0277	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000719	0.0251	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00069	0.0241	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00063	0.022	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.0006	0.021	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000551	0.0192	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000545	0.019	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000503	0.0176	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000425	0.0148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000407	0.0142	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000356	0.0124	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000345	0.012	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000323	0.0113	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000322	0.0112	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000311	0.0109	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000297	0.0104	CbGpPWpGaD
Raltegravir—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000292	0.000404	CcSEcCtD
Raltegravir—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000292	0.000404	CcSEcCtD
Raltegravir—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000403	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000289	0.000401	CcSEcCtD
Raltegravir—Infection—Etoposide—peripheral nervous system neoplasm	0.000289	0.0004	CcSEcCtD
Raltegravir—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000289	0.0004	CcSEcCtD
Raltegravir—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000288	0.000399	CcSEcCtD
Raltegravir—Nausea—Melphalan—peripheral nervous system neoplasm	0.000288	0.000399	CcSEcCtD
Raltegravir—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000398	CcSEcCtD
Raltegravir—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000397	CcSEcCtD
Raltegravir—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000285	0.000395	CcSEcCtD
Raltegravir—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000285	0.000394	CcSEcCtD
Raltegravir—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000393	CcSEcCtD
Raltegravir—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000284	0.000393	CcSEcCtD
Raltegravir—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000284	0.000393	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000283	0.00987	CbGpPWpGaD
Raltegravir—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000282	0.000391	CcSEcCtD
Raltegravir—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.00039	CcSEcCtD
Raltegravir—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000281	0.000389	CcSEcCtD
Raltegravir—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000388	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.000384	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000383	CcSEcCtD
Raltegravir—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000276	0.000382	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000276	0.000382	CcSEcCtD
Raltegravir—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000275	0.000381	CcSEcCtD
Raltegravir—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000274	0.00038	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.00038	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000274	0.00038	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000376	CcSEcCtD
Raltegravir—Pain—Cisplatin—peripheral nervous system neoplasm	0.000271	0.000376	CcSEcCtD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000271	0.000375	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000371	CcSEcCtD
Raltegravir—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000267	0.00037	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000267	0.00037	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000369	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000367	CcSEcCtD
Raltegravir—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000264	0.000366	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000264	0.00923	CbGpPWpGaD
Raltegravir—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000264	0.000365	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000364	CcSEcCtD
Raltegravir—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000262	0.000362	CcSEcCtD
Raltegravir—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000261	0.000362	CcSEcCtD
Raltegravir—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000361	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000359	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000259	0.000358	CcSEcCtD
Raltegravir—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000258	0.000358	CcSEcCtD
Raltegravir—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000258	0.000357	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000354	CcSEcCtD
Raltegravir—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000256	0.000354	CcSEcCtD
Raltegravir—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000255	0.000354	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000255	0.000353	CcSEcCtD
Raltegravir—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000255	0.000353	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000253	0.000351	CcSEcCtD
Raltegravir—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000253	0.000351	CcSEcCtD
Raltegravir—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000253	0.00035	CcSEcCtD
Raltegravir—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000251	0.000348	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000251	0.000348	CcSEcCtD
Raltegravir—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000251	0.000348	CcSEcCtD
Raltegravir—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000251	0.000347	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000251	0.000347	CcSEcCtD
Raltegravir—Constipation—Etoposide—peripheral nervous system neoplasm	0.000249	0.000344	CcSEcCtD
Raltegravir—Pain—Etoposide—peripheral nervous system neoplasm	0.000249	0.000344	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000344	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000341	CcSEcCtD
Raltegravir—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000246	0.000341	CcSEcCtD
Raltegravir—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000246	0.00034	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000338	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000335	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000334	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000241	0.000334	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.00024	0.000332	CcSEcCtD
Raltegravir—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.00024	0.000332	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.000331	CcSEcCtD
Raltegravir—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000239	0.000331	CcSEcCtD
Raltegravir—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000238	0.000329	CcSEcCtD
Raltegravir—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000237	0.000329	CcSEcCtD
Raltegravir—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000237	0.000328	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000328	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000328	CcSEcCtD
Raltegravir—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000235	0.000325	CcSEcCtD
Raltegravir—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000235	0.000325	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.000325	CcSEcCtD
Raltegravir—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000234	0.000324	CcSEcCtD
Raltegravir—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000233	0.000323	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000322	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000321	CcSEcCtD
Raltegravir—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000231	0.00032	CcSEcCtD
Raltegravir—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00023	0.000318	CcSEcCtD
Raltegravir—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00023	0.000318	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000318	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000316	CcSEcCtD
Raltegravir—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000228	0.000316	CcSEcCtD
Raltegravir—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000228	0.000315	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000314	CcSEcCtD
Raltegravir—Rash—Vincristine—peripheral nervous system neoplasm	0.000226	0.000314	CcSEcCtD
Raltegravir—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000226	0.000313	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000313	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000225	0.000312	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000312	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000312	CcSEcCtD
Raltegravir—Headache—Vincristine—peripheral nervous system neoplasm	0.000225	0.000311	CcSEcCtD
Raltegravir—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.00031	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000223	0.00779	CbGpPWpGaD
Raltegravir—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000223	0.000309	CcSEcCtD
Raltegravir—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000221	0.000307	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000306	CcSEcCtD
Raltegravir—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000217	0.000301	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	0.000217	0.0003	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000217	0.00757	CbGpPWpGaD
Raltegravir—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000297	CcSEcCtD
Raltegravir—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000214	0.000297	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000296	CcSEcCtD
Raltegravir—Nausea—Vincristine—peripheral nervous system neoplasm	0.000213	0.000295	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000295	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.000294	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000293	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.00029	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.00029	CcSEcCtD
Raltegravir—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000209	0.000289	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000289	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000288	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000288	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000287	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000207	0.000286	CcSEcCtD
Raltegravir—Chills—Epirubicin—peripheral nervous system neoplasm	0.000206	0.000285	CcSEcCtD
Raltegravir—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000206	0.000285	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000283	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—peripheral nervous system neoplasm	0.000203	0.000281	CcSEcCtD
Raltegravir—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000202	0.00028	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000278	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	0.000201	0.000278	CcSEcCtD
Raltegravir—Rash—Cisplatin—peripheral nervous system neoplasm	0.0002	0.000277	CcSEcCtD
Raltegravir—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.0002	0.000277	CcSEcCtD
Raltegravir—Erythema—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000277	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000277	CcSEcCtD
Raltegravir—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000199	0.000276	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000275	CcSEcCtD
Raltegravir—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000274	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000273	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000273	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000196	0.00686	CbGpPWpGaD
Raltegravir—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000271	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000269	CcSEcCtD
Raltegravir—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000268	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000267	CcSEcCtD
Raltegravir—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000192	0.000266	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000266	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.000265	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000191	0.00667	CbGpPWpGaD
Raltegravir—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.000264	CcSEcCtD
Raltegravir—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000189	0.000261	CcSEcCtD
Raltegravir—Alopecia—Doxorubicin—peripheral nervous system neoplasm	0.000188	0.00026	CcSEcCtD
Raltegravir—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000258	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000257	CcSEcCtD
Raltegravir—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000185	0.000256	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000256	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000256	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000256	CcSEcCtD
Raltegravir—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000254	CcSEcCtD
Raltegravir—Rash—Etoposide—peripheral nervous system neoplasm	0.000183	0.000254	CcSEcCtD
Raltegravir—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000183	0.000254	CcSEcCtD
Raltegravir—Headache—Etoposide—peripheral nervous system neoplasm	0.000182	0.000252	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000252	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000182	0.00635	CbGpPWpGaD
Raltegravir—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000251	CcSEcCtD
Raltegravir—Malaise—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000249	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000249	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000179	0.000249	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000248	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000244	CcSEcCtD
Raltegravir—Cough—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000241	CcSEcCtD
Raltegravir—Nausea—Etoposide—peripheral nervous system neoplasm	0.000173	0.000239	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000239	CcSEcCtD
Raltegravir—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.000238	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.000237	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000236	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000236	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000236	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000235	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000235	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000234	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000168	0.000233	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000167	0.00583	CbGpPWpGaD
Raltegravir—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000231	CcSEcCtD
Raltegravir—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000166	0.00023	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.00023	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000164	0.000228	CcSEcCtD
Raltegravir—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000226	CcSEcCtD
Raltegravir—Infection—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000224	CcSEcCtD
Raltegravir—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000223	CcSEcCtD
Raltegravir—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000221	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000221	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000221	CcSEcCtD
Raltegravir—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000219	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000218	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000218	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000218	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000218	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000217	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000216	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000155	0.000215	CcSEcCtD
Raltegravir—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000213	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000211	CcSEcCtD
Raltegravir—Infection—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000208	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000206	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000205	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000205	CcSEcCtD
Raltegravir—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000204	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000147	0.00512	CbGpPWpGaD
Raltegravir—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000203	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000203	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000202	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000145	0.000201	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000199	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000196	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000195	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000195	CcSEcCtD
Raltegravir—Pain—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000193	CcSEcCtD
Raltegravir—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000193	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.00019	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000189	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000188	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000186	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.000186	CcSEcCtD
Raltegravir—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000185	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000184	CcSEcCtD
Raltegravir—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000182	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00018	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00018	CcSEcCtD
Raltegravir—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000179	CcSEcCtD
Raltegravir—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000179	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000179	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000178	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000178	CcSEcCtD
Raltegravir—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000172	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000171	CcSEcCtD
Raltegravir—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000166	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000166	CcSEcCtD
Raltegravir—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000165	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000165	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000118	0.00412	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000162	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000116	0.00405	CbGpPWpGaD
Raltegravir—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000115	0.00016	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000154	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000154	CcSEcCtD
Raltegravir—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.00015	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000149	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000148	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GNS—peripheral nervous system neoplasm	0.000106	0.0037	CbGpPWpGaD
Raltegravir—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000144	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000143	CcSEcCtD
Raltegravir—Rash—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000142	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000142	CcSEcCtD
Raltegravir—Headache—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000141	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—NME1—peripheral nervous system neoplasm	0.000102	0.00355	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—peripheral nervous system neoplasm	9.97e-05	0.000138	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—COX2—peripheral nervous system neoplasm	9.78e-05	0.00341	CbGpPWpGaD
Raltegravir—Nausea—Epirubicin—peripheral nervous system neoplasm	9.68e-05	0.000134	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—peripheral nervous system neoplasm	9.59e-05	0.000133	CcSEcCtD
Raltegravir—Rash—Doxorubicin—peripheral nervous system neoplasm	9.51e-05	0.000132	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	9.5e-05	0.000132	CcSEcCtD
Raltegravir—Headache—Doxorubicin—peripheral nervous system neoplasm	9.45e-05	0.000131	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.17e-05	0.0032	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—peripheral nervous system neoplasm	8.96e-05	0.000124	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.64e-05	0.00302	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	8.4e-05	0.00293	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.32e-05	0.00291	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.63e-05	0.00266	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.98e-05	0.00244	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.5e-05	0.00227	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ENO2—peripheral nervous system neoplasm	6.42e-05	0.00224	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—BCHE—peripheral nervous system neoplasm	5.42e-05	0.00189	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.34e-05	0.00186	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.17e-05	0.00181	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.1e-05	0.00178	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TH—peripheral nervous system neoplasm	5.1e-05	0.00178	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.51e-05	0.00157	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GNAS—peripheral nervous system neoplasm	4.16e-05	0.00145	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ABCB1—peripheral nervous system neoplasm	4.08e-05	0.00143	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—peripheral nervous system neoplasm	1.12e-05	0.000392	CbGpPWpGaD
